Kerri-Ann Millar
Net Worth
Last updated:
What is Kerri-Ann Millar net worth?
The estimated net worth of Ms. Kerri-Ann Millar is at least $2,858,816 as of 21 Aug 2022. She owns shares worth $8,483 as insider, has earned $17,783 from insider trading and has received compensation worth at least $2,832,550 in Cue Biopharma, Inc..
What is the salary of Kerri-Ann Millar?
Ms. Kerri-Ann Millar salary is $404,650 per year as Chief Financial Officer in Cue Biopharma, Inc..
How old is Kerri-Ann Millar?
Ms. Kerri-Ann Millar is 55 years old, born in 1970.
What stocks does Kerri-Ann Millar currently own?
As insider, Ms. Kerri-Ann Millar owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | Chief Financial Officer | 10,472 | $0.81 | $8,483 |
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Kerri-Ann Millar insider trading
Cue Biopharma, Inc.
Ms. Kerri-Ann Millar has made only one insider trade between 2018-2022, according to the Form 4 filled with the SEC.
As of 21 Aug 2022 she still owns at least 10,472 units of CUE stock.
Cue Biopharma key executives
Cue Biopharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Anish Suri Ph.D. (51) Pres & Chief Scientific Officer
- Mr. Daniel R. Passeri M.Sc., MSc., J.D. (64) Chief Executive Officer & Director
- Ms. Kerri-Ann Millar (55) Chief Financial Officer